Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
This is specifically for the evaluation of medicines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
The report also revealed that 87% of physicians agreed that FEE recommendations would help to improve the speed of recovery
Subscribe To Our Newsletter & Stay Updated
